Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point-of-care COVID-19 antigen testing in German emergency rooms - a cost-benefit analysis.

Pulmonology·2021
Same author

Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals.

Pneumologie (Stuttgart, Germany)·2021
Same author

Systematic rifampicin resistance errors with Xpert<sup>®</sup> MTB/RIF Ultra: implications for regulation of genotypic assays.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[125 Years German Central Committee for the Fight against Tuberculosis (DZK)].

Pneumologie (Stuttgart, Germany)·2020
Same author

[The New WHO Guidelines for Rapid Diagnostics and Treatment of Drug-Resistant Tuberculosis Commented for Germany, Austria and Switzerland].

Pneumologie (Stuttgart, Germany)·2020
Same journal

Pneumologie (Stuttgart, Germany)·2026
Same journal

Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Correction: Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Erratum: Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Acute lung failure].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[The internet as a source of information for patients with sarcoidosis].

Pneumologie (Stuttgart, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

[Tuberculosis - historical development, current status, future prospects].

R Loddenkemper1, R Diel, T Schaberg

  • 1Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose, Berlin. rloddenkemper@dzk-tuberkulose.de

Pneumologie (Stuttgart, Germany)
|September 10, 2010
PubMed
Summary
This summary is machine-generated.

Tuberculosis (TB) remains a leading global cause of death, with worsening trends due to HIV and drug-resistant strains. Concerted international action and research are crucial to manage this urgent public health crisis.

Related Experiment Videos

Last Updated: Jun 9, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Context:

  • Tuberculosis (TB) is a historical and ongoing leading cause of mortality worldwide.
  • Despite declining incidence in industrialized nations like Germany, global TB rates are rising.
  • HIV coinfection and the emergence of polyresistant TB strains exacerbate the global crisis.

Purpose:

  • To highlight the persistent and worsening global threat of tuberculosis.
  • To emphasize the critical need for international collaboration and research in combating TB.

Summary:

  • Tuberculosis continues to be a major global health challenge, ranking among the top ten causes of death.
  • The spread of HIV and multidrug-resistant TB strains are driving a dramatic worsening of the global situation.
  • Effective management requires urgent, coordinated international efforts and advancements in diagnostics, treatments, and vaccines.

Impact:

  • Failure to act decisively risks an unmanageable TB epidemic, even with advanced 21st-century technology.
  • Intensified research into new TB diagnostics, therapeutics, and vaccines is essential for future control.
  • Cooperative action involving affected countries is vital to prevent a global health catastrophe.